Here’s what you should know:
1. Early in the process, shareholders expressed fears about the debt the company would take on through the deal.
2. Takeda must hold a meeting to record shareholder votes by Jan. 18.
3. Takeda secured a $30.9 billion bridge loan to fund the acquisition. Some investors are concerned about Takeda taking on that much debt.
4. In addition to investor approval, Takeda still needs to earn European Commission approval. The European Commission expressed monopolistic concerns over the company’s competing gastrointestinal treatments.
More articles on healthcare:
3 thoughts on managing denials from employer plans
GI societies slam CMS decision to side with Anthem, devalue GI codes — 5 insights
USPI delivers $502M operating revenue in Q3, Tenet’s hospital operations disappoint
